Literature DB >> 6322507

Infantile spasms: modern practical aspects.

R Riikonen.   

Abstract

Data on incidence, aetiology, therapy and prognosis of infantile spasms are reviewed. In a large proportion of cases the aetiological factors of infantile spasms can now be established with some certainty. Especially the new neuroradiological and virological investigative methods have enabled a more accurate diagnosis. There have been changes in the aetiologic pattern over the years. The optimal dosage and duration of ACTH or glucocorticoid therapy have not yet been established. In the Finnish study the large ACTH doses (120-160 IE) generally used in many Nordic countries did not carry a better prognosis than the smaller doses (20-40 IE). Side-effects of ACTH therapy are relatively common. They are more frequent with large doses than with smaller ones. Measures can be taken to prevent or treat part of them. The prognosis and related factors in infantile spasms as well as some recommendations to improve them are reviewed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322507     DOI: 10.1111/j.1651-2227.1984.tb09889.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  4 in total

Review 1.  A risk-benefit assessment of treatments for infantile spasms.

Authors:  R Nabbout
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Epilepsy and associated handicaps in a 1 year birth cohort in northern Finland.

Authors:  L von Wendt; P Rantakallio; A L Saukkonen; H Mäkinen
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

3.  Computerized tomography of brain in infantile spasms (West syndrome).

Authors:  A H Mahdi; M D Yohannan; P J Patel; T M Malabarey; T M Kolawole
Journal:  Pediatr Radiol       Date:  1990

Review 4.  Prenatal corticosteroids modify glutamatergic and GABAergic synapse genomic fabric: insights from a novel animal model of infantile spasms.

Authors:  D A Iacobas; S Iacobas; T Chachua; C Goletiani; G Sidyelyeva; J Velíšková; L Velíšek
Journal:  J Neuroendocrinol       Date:  2013-11       Impact factor: 3.627

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.